Patients in dark over drug effects

PRODUCERS of one the most common anti-depressant drugs on the market are again embroiled in controversy over whether patients have been informed of its full effects.

The Irish Medicines Board, the regulatory authority for drugs, has told GlaxoSmithKline to change the patient information it gives out with Seroxat.

The leaflet claims that the drug works by returning serotonin levels to normal. However, doctors say the link between depression and serotonin levels is unproved.